Journal of Clinical Oncology, Vol 18, Issue 1
(January), 2000: 195
© 2000 American Society for Clinical Oncology
Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and Cisplatin
By Maja J. A. de Jonge,
Jaap Verweij,
Peter de Bruijn,
Eric Brouwer,
Ron H. J. Mathijssen,
Robbert J. van Alphen,
Maureen M. de Boer-Dennert,
Laurent Vernillet,
Christian Jacques,
Alex Sparreboom
From the Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, the Netherlands; and Rhône-Poulenc Rorer, Antony, France.
Address reprint requests to M.J.A. de Jonge, MD, PhD, Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, the Netherlands.
PURPOSE: To investigate the pharmacokinetics and pharmacodynamics of irinotecan and cisplatin administered once every 3 weeks in a dose-escalating study in patients with solid tumors.
PATIENTS AND METHODS: Fifty-two cancer patients were treated with irinotecan administered as a 90-minute infusion at doses ranging from 175 to 300 mg/m2 followed by cisplatin administered as a 3-hour intravenous infusion at doses ranging from 60 to 80 mg/m2. After reaching the maximum-tolerated dose, the sequence of drug administration was revised. For pharmacokinetic analysis, serial plasma samples were obtained on days 1 through 3 of the first cycle. Forty-five patients were assessable for irinotecan pharmacokinetics, and 46 were assessable for cisplatin pharmacokinetics.
RESULTS: Irinotecan and cisplatin demonstrated linear pharmacokinetics comparable to that observed with single-agent administration, which suggests an absence of pharmacokinetic interaction. SN-38G constituted the major plasma metabolite of irinotecan, whereas 7-ethyl-10-[4-N-(1-piperidino)1-amino]-carbonyloxycamptothecine (NPC) was only a minor metabolite in plasma, possibly indicating a rapid conversion of NPC to SN-38. The terminal elimination phases of SN-38 and SN-38G were similar and relatively delayed when compared with the elimination of irinotecan. Maximal DNA adduct formation did not significantly differ from that observed with single-agent administration. The percentage decrease in WBC was significantly related to the areas under the plasma concentration-time curve (AUCs) of the lactone form of irinotecan (P = .0245) and SN-38 (P = .0123). The severity of diarrhea was not significantly related to the AUCs of irinotecan and SN-38, nor to the systemic glucuronidation rate of SN-38.
CONCLUSION: There was no apparent pharmacokinetic interaction between irinotecan and cisplatin in this study. Reversion of the administration sequence of the drugs did not seem to have any influence on the pharmacokinetics. The incidence and severity of delayed-type diarrhea was not related to any of the studied parameters.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J. M. van der Bol, R. H.J. Mathijssen, W. J. Loos, L. E. Friberg, R. H.N. van Schaik, M. J.A. de Jonge, A. S.Th. Planting, J. Verweij, A. Sparreboom, and F. A. de Jong
Cigarette Smoking and Irinotecan Treatment: Pharmacokinetic Interaction and Effects on Neutropenia
J. Clin. Oncol.,
July 1, 2007;
25(19):
2719 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Carlini, N. J. Meropol, J. Bever, M. L. Andria, T. Hill, P. Gold, A. Rogatko, H. Wang, and R. L. Blanchard
UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan
Clin. Cancer Res.,
February 1, 2005;
11(3):
1226 - 1236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. J. Mathijssen, F. A. de Jong, R. H. N. van Schaik, E. R. Lepper, L. E. Friberg, T. Rietveld, P. de Bruijn, W. J. Graveland, W. D. Figg, J. Verweij, et al.
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
J Natl Cancer Inst,
November 3, 2004;
96(21):
1585 - 1592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. de Jong, S. Marsh, R. H. J. Mathijssen, C. King, J. Verweij, A. Sparreboom, and H. L. McLeod
ABCG2 Pharmacogenetics: Ethnic Differences in Allele Frequency and Assessment of Influence on Irinotecan Disposition
Clin. Cancer Res.,
September 1, 2004;
10(17):
5889 - 5894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Prados, W.K.A. Yung, K. A. Jaeckle, H. I. Robins, M. P. Mehta, H. A. Fine, P. Y. Wen, T. F. Cloughesy, S. M. Chang, M. K. Nicholas, et al.
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study
Neuro-oncol,
January 1, 2004;
6(1):
44 - 54.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A.-K. Souid, R. L. Dubowy, S. M. Blaney, L. Hershon, J. Sullivan, W. D. McLeod, and M. L. Bernstein
Phase I Clinical and Pharmacologic Study of Weekly Cisplatin and Irinotecan Combined with Amifostine for Refractory Solid Tumors
Clin. Cancer Res.,
February 1, 2003;
9(2):
703 - 710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Baker, J. Verweij, E. K. Rowinsky, R. C. Donehower, J. H. M. Schellens, L. B. Grochow, and A. Sparreboom
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
J Natl Cancer Inst,
December 18, 2002;
94(24):
1883 - 1888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Xie, R. H.J. Mathijssen, A. Sparreboom, J. Verweij, and M. O. Karlsson
Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis
J. Clin. Oncol.,
August 1, 2002;
20(15):
3293 - 3301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F.S. Kehrer, R. H.J. Mathijssen, J. Verweij, P. de Bruijn, and A. Sparreboom
Modulation of Irinotecan Metabolism by Ketoconazole
J. Clin. Oncol.,
July 15, 2002;
20(14):
3122 - 3129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H.J. Mathijssen, J. Verweij, M. J.A. de Jonge, K. Nooter, G. Stoter, and A. Sparreboom
Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations
J. Clin. Oncol.,
January 1, 2002;
20(1):
81 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kozuch, M. L. Grossbard, A. Barzdins, M. Araneo, A. Robin, D. Frager, P. Homel, J. Marino, P. DeGregorio, and H.W. Bruckner
Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer
Oncologist,
December 1, 2001;
6(6):
488 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. E. de Jongh, J. Verweij, W. J. Loos, R. de Wit, M. J.A. de Jonge, A. S.T. Planting, K. Nooter, G. Stoter, and A. Sparreboom
Body-Surface Area-Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure
J. Clin. Oncol.,
September 1, 2001;
19(17):
3733 - 3739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom
Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)
Clin. Cancer Res.,
August 1, 2001;
7(8):
2182 - 2194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. S. Kehrer, A. Sparreboom, J. Verweij, P. de Bruijn, C. A. Nierop, J. van de Schraaf, E. J. Ruijgrok, and M. J. A. de Jonge
Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients
Clin. Cancer Res.,
May 1, 2001;
7(5):
1136 - 1141.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. F. S. Kehrer, W. Yamamoto, J. Verweij, M. J. A. de Jonge, P. de Bruijn, and A. Sparreboom
Factors Involved in Prolongation of the Terminal Disposition Phase of SN-38: Clinical and Experimental Studies
Clin. Cancer Res.,
September 1, 2000;
6(9):
3451 - 3458.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. J. A. de Jonge, A. Sparreboom, A. S. T. Planting, M. E. L. van der Burg, M. M. de Boer-Dennert, J. t. Steeg, C. Jacques, and J. Verweij
Phase I Study of 3-Week Schedule of Irinotecan Combined With Cisplatin in Patients With Advanced Solid Tumors
J. Clin. Oncol.,
January 5, 2000;
18(1):
187 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
